Zubin Bham, MD
Pulmonary Disease · Norwalk, CTNPI 1407230477
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.8%), consulting fees and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Boehringer Ingelheim at 38.2% of the total. That places this record below the midpoint for pulmonary disease clinicians in CT, where the typical reported total is $1,017.
Across 14 payments — averaging $40.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$216
- Jazz Pharmaceuticals Inc.$150
- Harmony Biosciences LLC$100
- Takeda Pharmaceuticals U.S.A., Inc.$37
- E.r. Squibb & Sons, L.L.C.$24
- AstraZeneca$21
- plus $18 from 1 others
What the payments were for
- Consulting fees$15027%
- Food & beverage$31656%
- Education$10018%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 7 | $216 |
| Jazz Pharmaceuticals Inc. | 1 | $150 |
| Harmony Biosciences LLC | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| AstraZeneca | 1 | $21 |
| Lilly USA, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$566 in reported general payments places this provider in the 40th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Armodafinil | 22 | $1,441 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Norwalk
- Geoffrey ChuppNew Haven$1.2M
- Tapas BandyopadhyayWest Hartford$483K
- Raj ParikhHartford$386K
- Patrick TroyHartford$385K
- Michael ImevboreNew Haven$323K
- Jeffrey NascimentoHartford$213K
- Thinesh DahanayakeNorwich$192K
- Naftali KaminskiNew Haven$180K
- Daniel GerardiHartford$156K
- Roman SpivakAnsonia$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.